Attached files
| file | filename |
|---|---|
| 10-K - FORM 10-K - NOVELION THERAPEUTICS INC. | d293106d10k.htm |
| EX-21 - EXHIBIT 21 - NOVELION THERAPEUTICS INC. | d293106dex21.htm |
| EX-23 - EXHIBIT 23 - NOVELION THERAPEUTICS INC. | d293106dex23.htm |
| EX-31.2 - EXHIBIT 31.2 - NOVELION THERAPEUTICS INC. | d293106dex312.htm |
| EX-32.1 - EXHIBIT 32.1 - NOVELION THERAPEUTICS INC. | d293106dex321.htm |
| EX-31.1 - EXHIBIT 31.1 - NOVELION THERAPEUTICS INC. | d293106dex311.htm |
| EXCEL - IDEA: XBRL DOCUMENT - NOVELION THERAPEUTICS INC. | Financial_Report.xls |
| EX-32.2 - EXHIBIT 32.2 - NOVELION THERAPEUTICS INC. | d293106dex322.htm |
EXHIBIT 11
COMPUTATION OF PER SHARE EARNINGS
Basic net income per common share is computed using the weighted average number of common shares outstanding during the period. Diluted net income per common share is computed in accordance with the treasury stock method and the “if converted” method, which uses the weighted average number of common shares outstanding during the period and also includes the dilutive effect of potentially issuable common stock from outstanding stock options, warrants, and convertible debt. Common shares issuable upon exercise of certain options and warrants are not used in the calculation for the years ended December 31, 2007 to 2011, as the effect would be anti-dilutive.
| Year ended December 31, | ||||||||||||||||||||
| 2011 | 2010 | 2009 | 2008 | 2007 | ||||||||||||||||
| (In thousands of U.S. dollars except per share information) | ||||||||||||||||||||
| Net loss from continuing operations |
$ | (30,416 | ) | $ | (17,539 | ) | $ | (36,220 | ) | $ | (9,247 | ) | $ | (125,537 | ) | |||||
| Income from discontinued operations, net of income tax |
— | — | 135,654 | 144,138 | 15,540 | |||||||||||||||
| Net (loss) income available to common shareholders |
$ | (30,416 | ) | $ | (17,539 | ) | $ | 99,434 | $ | 134,891 | $ | (109,997 | ) | |||||||
| Basic and diluted net (loss) income per common share |
||||||||||||||||||||
| Continuing operations |
$ | (0.61 | ) | $ | (0.33 | ) | $ | (0.64 | ) | $ | (0.12 | ) | $ | (1.68 | ) | |||||
| Discontinued operations |
— | — | 2.41 | 1.93 | 0.21 | |||||||||||||||
| Net (loss) income |
$ | (0.61 | ) | $ | (0.33 | ) | $ | 1.77 | $ | 1.81 | $ | (1.47 | ) | |||||||
| Weighted average number of common shares outstanding (in thousands) |
50,105 | 52,382 | 56,194 | 74,620 | 74,907 | |||||||||||||||
| Diluted weighted average number of common shares outstanding (in thousands) |
50,105 | 52,382 | 56,194 | 74,620 | 74,907 | |||||||||||||||